Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
PLoS One ; 13(8): e0203293, 2018.
Artigo em Inglês | MEDLINE | ID: mdl-30161205

RESUMO

METHODS: Ninety-six-week costs for antiretroviral drugs, adverse event management, and HIV care for individuals initiating RAL, ATV/r, or DRV/r as first-line therapy for HIV-1 infection were estimated using an economic model. Efficacy and safety data (mean CD4 cell count changes, discontinuation rates, grade 3/4 adverse event incidence) for each regimen through 96 weeks of treatment were taken from the ACTG 5257 clinical trial. Antiretroviral drug costs for each initial regimen and for each substitution regimen, as used by individuals who discontinued their initial regimen, were based on wholesale acquisition costs. Adverse event management costs and HIV care costs, stratified by CD4 cell count range, were taken from published sources and inflated to 2016 dollars. Scenario and sensitivity analyses were conducted to assess the robustness of the results. Cost outcomes were discounted at an annual rate of 3.0%. RESULTS: Total 96-week costs were $81,231 for RAL, $88,064 for ATV/r, and $87,680 for DRV/r, where differences were primarily due to lower antiretroviral drug costs for RAL than for ATV/r or DRV/r. These results were found to be robust in scenario and sensitivity analyses. CONCLUSIONS: Relative to the DRV/r and ATV/r regimens, the RAL regimen had the lowest cost for treatment-naive adults with HIV-1 infection in the United States.


Assuntos
Fármacos Anti-HIV/economia , Fármacos Anti-HIV/uso terapêutico , Infecções por HIV/tratamento farmacológico , Infecções por HIV/economia , HIV-1 , Adulto , Fármacos Anti-HIV/efeitos adversos , Sulfato de Atazanavir/efeitos adversos , Sulfato de Atazanavir/economia , Sulfato de Atazanavir/uso terapêutico , Análise Custo-Benefício , Darunavir/efeitos adversos , Darunavir/economia , Darunavir/uso terapêutico , Quimioterapia Combinada , Feminino , Custos de Cuidados de Saúde , Humanos , Masculino , Modelos Econômicos , Raltegravir Potássico/efeitos adversos , Raltegravir Potássico/economia , Raltegravir Potássico/uso terapêutico , Ritonavir/efeitos adversos , Ritonavir/economia , Ritonavir/uso terapêutico , Estados Unidos
3.
J Med Econ ; 19(4): 386-96, 2016.
Artigo em Inglês | MEDLINE | ID: mdl-26640980

RESUMO

OBJECTIVES: Atazanavir (ATV) and darunavir (DRV) are protease inhibitors approved for HIV treatment in combination with ritonavir (/r). The objectives of this study were to compare persistence (time to treatment discontinuation/modification), adherence, and healthcare costs among patients with human immunodeficiency virus (HIV) initiating ATV/r or DRV/r. METHODS: This retrospective cohort study used commercial and Medicaid administrative insurance claims data. Patients initiating ATV/r or DRV/r from 2006-2013 with continuous enrollment for ≥6 months before and ≥3 months after initiation were included. Patients were followed from initiation until discontinuation/modification (≥30 day gap in ATV or DRV or initiation of a new antiretroviral medication), during which time adherence (proportion of days covered [PDC], with PDC ≥80% or 95% considered adherent) and per-patient per-month (PPPM) total healthcare costs were measured. DRV/r patients were propensity score matched to ATV/r patients at a 1:1 ratio to achieve balance on potentially confounding demographic and clinical factors. Commercial and Medicaid samples were analyzed separately, as were antiretroviral (ART)-naïve and experienced patients. RESULTS: The final samples comprised 2988 commercially-insured and 1158 Medicaid-insured patients. There were no significant differences in hazards of discontinuation/modification between the ATV/r or DRV/r cohorts. With respect to odds of being adherent, the only marginally significant result was comparing odds of achieving PDC ≥80% among ART-naïve Medicaid patients, which favored ATV/r. All other adherence comparisons were not significant. Although ATV/r cohorts tended to have lower PPPM costs, the majority of these differences were not statistically significant. CONCLUSIONS: Patients with HIV treated with either ATV/r or DRV/r had similar time to treatment discontinuation/modification, adherence, and monthly healthcare costs. Results were similar across the pre-specified sub-groups. These findings are useful not only as an insight into clinical practice, but also as a resource for healthcare providers and payers evaluating treatment options for HIV+ individuals.


Assuntos
Fármacos Anti-HIV/administração & dosagem , Sulfato de Atazanavir/economia , Sulfato de Atazanavir/uso terapêutico , Darunavir/economia , Darunavir/uso terapêutico , Infecções por HIV/tratamento farmacológico , Infecções por HIV/economia , Adulto , Fármacos Anti-HIV/uso terapêutico , Sulfato de Atazanavir/administração & dosagem , Darunavir/administração & dosagem , Quimioterapia Combinada , Feminino , Gastos em Saúde/estatística & dados numéricos , Serviços de Saúde/economia , Serviços de Saúde/estatística & dados numéricos , Humanos , Masculino , Medicaid/estatística & dados numéricos , Adesão à Medicação/estatística & dados numéricos , Pessoa de Meia-Idade , Modelos Econométricos , Pontuação de Propensão , Estudos Retrospectivos , Ritonavir/uso terapêutico , Fatores Socioeconômicos , Estados Unidos
4.
Pharmacoeconomics ; 32(9): 903-17, 2014 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-24906477

RESUMO

OBJECTIVE: The AntiRetroviral Therapy with TMC114 ExaMined In naive Subjects (ARTEMIS) clinical trial examined the efficacy and safety of two ritonavir-boosted protease inhibitors (PI/r), darunavir/r 800/100 mg once daily (QD) and lopinavir/r 800/200 mg daily, both used in combination with tenofovir disoproxil fumarate/emtricitabine. This study aimed to assess the cost effectiveness of the darunavir/r regimen compared with the lopinavir/r regimen in treatment-naive adults with HIV-1 infection in Canada. METHODS: A Markov model with a 3-month cycle time and six CD4 cell-count-based health states (>500, 351-500, 201-500, 101-200, 51-100, and 0-50 cells/mm(3)) followed a cohort of treatment-naive adults with HIV-1 infection through initial darunavir/r or lopinavir/r combination therapy and a common set of subsequent regimens over the course of their remaining lifetimes. Population characteristics and transition probabilities were estimated from the ARTEMIS clinical trial and other trials. Costs (in 2014 Canadian dollars), utilities, and mortality were estimated from Canadian sources and published literature. Costs and health outcomes were discounted at 5% per year. One-way and probabilistic sensitivity analyses were performed, including a simple indirect comparison of the darunavir/r initial regimen with an atazanavir/r-based regimen. RESULTS: In the base-case lifetime analysis, individuals receiving initial therapy with the darunavir/r regimen experienced 0.25 more quality-adjusted life-years (QALYs) with lower antiretroviral drug costs (-$14,246) and total costs (-$18,402) than individuals receiving the lopinavir/r regimen, indicating that darunavir/r dominated lopinavir/r. In an indirect comparison with an atazanavir/r-based regimen, the darunavir/r regimen remained the dominant choice, but with lower cost savings (-$2,303) and QALY gains (0.02). Results were robust to a wide range of other changes in input parameter values, population characteristics, and modeling assumptions. The probabilistic sensitivity analysis demonstrated that the darunavir/r regimen was cost effective compared with the lopinavir/r regimen in over 86% of simulations for willingness-to-pay thresholds between $0 and $100,000 per QALY gained. CONCLUSIONS: Darunavir/r 800/100 mg QD may be a cost-effective PI/r component of initial antiretroviral therapy for treatment-naive adults with HIV-1 infection in Canada.


Assuntos
Análise Custo-Benefício , Darunavir/economia , Combinação de Medicamentos , Infecções por HIV/tratamento farmacológico , Infecções por HIV/economia , Inibidores da Protease de HIV/economia , Lopinavir/economia , Ritonavir/economia , Adulto , Terapia Antirretroviral de Alta Atividade , Contagem de Linfócito CD4 , Canadá , Ensaios Clínicos Fase III como Assunto , Darunavir/efeitos adversos , Combinação Emtricitabina e Fumarato de Tenofovir Desoproxila , HIV-1 , Humanos , Lopinavir/efeitos adversos , Cadeias de Markov
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...